AI Article Synopsis
- A 95-year-old man was diagnosed with high-grade B-cell lymphoma and hairy cell leukemia, two types of lymphomas discovered during his hospitalization for erysipelas in 2018.
- Traditional treatments like R-CHOP and rituximab were unsuccessful, and the BTK inhibitor was not an option due to the patient's high blood pressure.
- Ultimately, the patient was treated with venetoclax for two years, leading to improved health and indicating that targeted therapies may be safer and more effective for elderly patients with multiple lymphomas.
Article Abstract
This case report discusses a 95-year-old man diagnosed with two types of lymphomas. He was hospitalized for erysipelas in September 2018. The lymph node revealed high-grade B-cell lymphoma with Myc and Bcl-2 rearrangement. Bone marrow biopsy revealed hairy cell leukemia, a rare type of indolent B-cell lymphoma. We found that the bone marrow and left inguinal lymph node were non-homologous. There are no known reports of super-aged patients with two types of lymphoma simultaneously. The toxicity of R-CHOP in elderly people limited its usage, so we first chose rituximab. However, this approach was not successful. We then considered the Bruton tyrosine kinase (BTK) inhibitor, but its use was limited due to high blood pressure. Finally, we administered venetoclax, which the patient took for 2 years. The results of the routine blood examination were close to normal and no enlarged superficial or abdominal lymph nodes were observed.This is the oldest reported patient with two types of malignant lymphatic diseases. Additionally, this rare case suggests that targeted therapy can be more effective and safe for super-aged individuals. To summarize, a 95-year-old man diagnosed with two types of lymphomas, high-grade B-cell lymphoma and hairy cell leukemia, was successfully treated with venetoclax after other treatments failed. This case suggests that targeted therapy can be effective and safe for super-aged patients with multiple malignant lymphatic system diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11258385 | PMC |
| http://dx.doi.org/10.1016/j.lrr.2024.100457 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diffuse Large B-Cell Lymphoma With the "Leopard Man" Appearance on 18F-FDG PET/CT.
Clin Nucl Med
January 2025
From the Department of Nuclear Medicine, Central People's Hospital of Zhanjiang, Zhanjiang, China.
Subcutaneous nodules and masses as the primary manifestation of diffuse large B-cell lymphoma are exceedingly rare. We present 18F-FDG PET/CT findings of multiple hypermetabolic nodules and masses distributed throughout the body, creating a characteristic "leopard man" appearance on the MIP image, in a 65-year-old man. An excisional biopsy of the right thigh mass confirmed the diagnosis of diffuse large B-cell lymphoma.
View Article and Find Full Text PDFMicroRNA as a Potential Diagnostic and Prognostic Biomarker in Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.
Cancer Rep (Hoboken)
January 2025
Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.
Background: Recently, microRNAs (miRNAs) have been applied as biomarkers for diffuse large B-cell lymphoma (DLBCL) patients. Early diagnosis and management of DLBCL can improve patient survival and prognosis.
Aims: This systematic review and meta-analysis aimed to evaluate the diagnostic and prognostic accuracy of miRNA biomarkers in DLBCL patients.
Upregulation of CD19 by low-dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma.
Discov Oncol
January 2025
Department of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
B-cell non-Hodgkin lymphoma (B-NHL) is a highly heterogeneous group of lymphopoietic malignancies that account for 85% to 90% of all non-Hodgkin lymphomas. In recent years, CD19 Chimeric antigen receptor T (CAR T) cell immunotherapy has significantly improved the cure rate of B-NHL patients, but there are still some patients who cannot achieve remission after treatment, or relapse after remission. Therefore, it is of great importance to overcome the drug resistance of CD19 CAR T cells after B-NHL treatment and reduce the recurrence rate of CD19 CAR T cells after B-NHL treatment.
View Article and Find Full Text PDFCentral nervous system involvement in Waldenström macroglobulinemia: a comparative population-based study of Bing-Neel syndrome and histological transformation.
Ann Hematol
January 2025
Department of Pathology, Copenhagen University Hospital - Zealand University Hospital Roskilde, Roskilde, Denmark.
Central nervous system (CNS) involvement in Waldenström macroglobulinemia (WM) is a rare complication that can manifest as Bing-Neel syndrome (BNS) or as histological transformation (HT) to diffuse large B-cell lymphoma (DLBCL). We report data from a single-center cohort of 469 patients consecutively diagnosed with WM between 2000 and 2022. BNS was identified in 1.
View Article and Find Full Text PDFDetecting B-cell lymphoma-6 overexpression status in primary central nervous system lymphoma using multiparametric MRI-based machine learning.
Neuroradiology
January 2025
Medical School of Chinese PLA, No.28 Fuxing Road, Haidian District, Beijing, 100853, China.
Purpose: In primary central nervous system lymphoma (PCNSL), B-cell lymphoma-6 (BCL-6) is an unfavorable prognostic biomarker. We aim to non-invasively detect BCL-6 overexpression in PCNSL patients using multiparametric MRI and machine learning techniques.
Methods: 65 patients (101 lesions) with primary central nervous system lymphoma (PCNSL) diagnosed from January 2013 to July 2023, and all patients were randomly divided into a training set and a validation set according to a ratio of 8 to 2.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!